The HSP90 inhibitor onalespib potentiates (177)Lu-DOTATATE therapy in neuroendocrine tumor cells

(177)Lu-DOTATATE was recently approved for the treatment of somatostatin receptor (SSTR)-positive neuroen-docrine tumors (NETs). However, despite impressive response rates, complete responses are rare. Heat shock protein 90 (HSP90) inhibitors have been suggested as suitable therapeutic agents for NE...

Descripción completa

Detalles Bibliográficos
Autores principales: Lundsten, Sara, Spiegelberg, Diana, Stenerlöw, Bo, Nestor, Marika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831206/
https://www.ncbi.nlm.nih.gov/pubmed/31638190
http://dx.doi.org/10.3892/ijo.2019.4888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831206/
https://www.ncbi.nlm.nih.gov/pubmed/31638190
http://dx.doi.org/10.3892/ijo.2019.4888

Ejemplares similares